from Reuters: Health News https://ift.tt/2Bs7Nk2
Novartis's pricing might be tested with costly eye therapy
Novartis's price-setting muscle is about to be tested after it won European Union approval for a blindness-fighting gene therapy whose $850,000 list cost in the United States has been labeled too expensive by some groups.
from Reuters: Health News https://ift.tt/2Bs7Nk2
from Reuters: Health News https://ift.tt/2Bs7Nk2
Subscribe to:
Post Comments (Atom)
-
The German cabinet will hold a secret session on Wednesday to discuss safeguard measures regarding the possible participation of China's...
-
Stocks poised for another day of gains Equity markets look to add to the gains from the prior session as investor concerns about the fu...
-
By LIAM STACK from NYT Magazine https://ift.tt/2FNPp6k
No comments:
Post a Comment